Abstract
Genome sequences from evolving infectious pathogens allow quantification of case introductions and local transmission dynamics. We sequenced 11,357 SARS-CoV-2 genomes from Switzerland in 2020 - the 6th largest effort globally. Using a representative subset of these data, we estimated viral introductions to Switzerland and their persistence over the course of 2020. We contrast these estimates with simple null models representing the absence of certain public health measures. We show that Switzerland’s border closures de-coupled case introductions from incidence in neighboring countries. Under a simple model, we estimate an 86 - 98% reduction in introductions during Switzerland’s strictest border closures. Furthermore, the Swiss 2020 partial lockdown roughly halved the time for sampled introductions to die out. Finally, we quantified local transmission dynamics once introductions into Switzerland occurred, using a novel phylodynamic model. We find that transmission slowed 35 – 63% upon outbreak detection in summer 2020, but not in fall. This finding may indicate successful contact tracing over summer before overburdening in fall. The study highlights the added value of genome sequencing data for understanding transmission dynamics.
One Sentence Summary Phylogenetic and phylodynamic methods quantify the drop in case introductions and local transmission with implementation of public health measures.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the Swiss National Science Foundation grant 31CA30_196267 (to TS) and ETH Zurich.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study involves only openly available pathogen genome sequence data collected from humans, which can be obtained from GISAID at gisaid.org. The Ethikkommission Nordwest- und Zentralschweiz (EKNZ) ruled on the ethics of genome sequence generation by the Swiss SARS-CoV-2 Sequencing Consortium (S3C) for this research. Ethical approval was waived as only viral material is processed.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Introduction estimation method updated.
Data Availability
All genome sequence data used in the analysis is available on GISAID (https://www.gisaid.org/). Data generated by the Swiss SARS-CoV-2 Sequencing Consortium is available on GISAID (submitting lab: Department of Biosystems Science and Engineering, ETH Zuerich). The code used to generate figures and values for the manuscript is available at https://github.com/SarahNadeau/cov-swiss-phylo. The phylogenetic analysis code is at https://github.com/cevo-public/Grapevine-SARS-CoV-2-Introduction-Analysis and the phylodynamic analysis code, including BEAST2 XML files, is at https://github.com/tgvaughan/TransmissionChainAnalyses.
